UCSF Helen Diller Family Comprehensive Cancer Center

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Retrieved on: 
Wednesday, August 30, 2023
Neoplasm, UCSF Helen Diller Family Comprehensive Cancer Center, Portage, Thomas Jefferson University, Calendar, Clinical trial, USC Norris Comprehensive Cancer Center, Lead, G&A, Toxicity, Research, Lung cancer, ASCO, Adenosine, PRTG, Acquisition, American Society of Clinical Oncology, Patient, Washington University School of Medicine, A2A, Society, MD Anderson Cancer Center, Safety, Prostate cancer, Fiscal, Pharmaceutical industry, Coal, Taro (river)

WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023.

Key Points: 
  • WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023.
  • R&D costs increased by approximately $1.7 million to approximately $3.6 million, or approximately 89%, for the Fiscal 2024 Quarter from approximately $1.9 million in the Fiscal 2023 Quarter.
  • G&A expenses decreased by approximately $0.8 million to approximately $1.4 million, or approximately 36%, from approximately $2.2 million in the Fiscal 2023 Quarter.
  • Professional fees decreased by $0.4 million, primarily attributable to legal fees associated with the Tarus acquisition in the Fiscal 2023 Quarter.

RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, June 20, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, SAB, Pancreatic cancer, Interim, University, Pancreatic Cancer Action Network, Hematology, Schering-Plough, Cancer, Jim Valvano, UCSF Helen Diller Family Comprehensive Cancer Center, Lustgarten Foundation for Pancreatic Cancer Research, NIH Intramural Research Program, ASCO, EORTC, UCSF, Patient, Division, United States Air Force Scientific Advisory Board, Research, NCI, Armendariz v. Foundation Health Psychcare Services, Inc., Pharmaceutical industry, Medicine

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).
  • She also serves as Chair of the NCCN Guidelines Panel on Pancreatic Cancer (since 2000), editor-in-chief of JNCCN, and on the ASCO Conquer Cancer Foundation Board.
  • Previously, Dr. Tempero has served on the ASCO Board of Directors, as ASCO President, and as a member of FDA’s Oncology Drug Advisory Committee.
  • She co-directed the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar courses in Europe and Australia.

CureMD Oncology Partners with Northern Marianas Oncology Center, Celebrates Expanded Reach to Saipan

Retrieved on: 
Tuesday, May 30, 2023
Oncology, Partnership, Workflow, CNMI, BSN, Patient, Cancer, RN, Commonwealth, Health information management, CHCC, UCSF Helen Diller Family Comprehensive Cancer Center, Nursing

CureMD is proud to help the Northern Marianas Oncology Center drive this mission forward with their best-in-class technology solutions for oncology.

Key Points: 
  • CureMD is proud to help the Northern Marianas Oncology Center drive this mission forward with their best-in-class technology solutions for oncology.
  • "We are thrilled to welcome the Northern Marianas Oncology Center as we continue to expand our reach across community oncology practices," said Wasif Toor, VP of Oncology, CureMD.
  • The Northern Marianas Oncology Center is a state-of-the-art cancer center that provides comprehensive cancer care and preventative screening to the people of Saipan and the Northern Marianas Islands.
  • "CureMD Oncology is an excellent fit for our cancer center," said MaryQuinn Rozkydal, RN, BSN, Oncology Nurse Manager, Northern Marianas Oncology Center.

University Cancer & Blood Center announces opening date of state-of-the art Comprehensive Cancer Treatment Center

Retrieved on: 
Tuesday, May 2, 2023
Oncology, UCBC, NCI-designated Cancer Center, Patient, Radiation, Surgical oncology, Sun Yat-sen University Cancer Center, NCI, Gastroenterology, UCSF Helen Diller Family Comprehensive Cancer Center, Clinical research, Palliative care, Nursing

ATHENS, Ga., May 2, 2023 /PRNewswire/ -- University Cancer & Blood Center (UCBC) will open its Comprehensive Cancer Center in August, offering a fully integrated approach to cancer care with incomparable, convenient access. This will be the first community cancer center of its kind in the region.

Key Points: 
  • ATHENS, Ga., May 2, 2023 /PRNewswire/ -- University Cancer & Blood Center (UCBC) will open its Comprehensive Cancer Center in August, offering a fully integrated approach to cancer care with incomparable, convenient access.
  • This will be the first community cancer center of its kind in the region.
  • "The UCBC Comprehensive Cancer Center offers the full spectrum of cancer care delivery," says Dr. Petros Nikolinakos, Managing Partner and Director of Clinical Research at UCBC.
  • Learn more about UCBC's Comprehensive Cancer Center: 706-353-2990, universitycancer.com.

Foundery Innovations Establishes Scientific Advisory Board with Appointment of Key Opinion Leaders in Immunology and Oncology

Retrieved on: 
Tuesday, March 28, 2023
SAB, Infection, University of California, San Diego, Maintenance, KOL, Human, University, Therapy, Biochemistry, Government Medical College, Texas A&M University, Biotechnology, UCSF Helen Diller Family Comprehensive Cancer Center, Research, Joslin Diabetes Center, Immunotherapy, Biology, Melanoma, Genentech, Translation, Harvard Medical School, Aix-Marseille University, Malignancy, School of Biological Sciences, University of Manchester, UCSF, Pathology, SAN, University of Washington Department of Bioengineering, School, Immune system, ILC2, Protein engineering, Knowledge, Entrepreneurship, Mouse, Cytokine, Health, Gene, Disease, Pharmaceutical industry, Vaccine, The Foundery

SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) -- Foundery Innovations (“Foundery”), a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced the establishment of its scientific advisory board (“SAB”) with the appointments of key opinion leaders (“KOLs”) in immunology, oncology, and protein engineering.

Key Points: 
  • SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) -- Foundery Innovations (“Foundery”), a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced the establishment of its scientific advisory board (“SAB”) with the appointments of key opinion leaders (“KOLs”) in immunology, oncology, and protein engineering.
  • Dr. Locksley’s laboratory pioneered the use of mice genetically engineered to express cytokines during allergic immune responses.
  • Foundery is in discussions with a handful of other KOLs and looks forward to announcing them in the coming months.
  • Additionally, Foundery’s scientific advisor pool is expected to grow in parallel with the Company’s portfolio expansion.

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Retrieved on: 
Monday, February 27, 2023
MD Anderson Cancer Center, Cancer, MD, UCSF Helen Diller Family Comprehensive Cancer Center, KOL, UCSF, Associate, University, Biomarker, Research, University of California, FDA, Patient, Adenosine, Immunosuppression, Cancer immunotherapy, Division, Tumor microenvironment, PRTG, Vaccine, Pharmaceutical industry

WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it will host a key opinion leader (KOL) webinar on targeting the adenosine pathway in cancer on Thursday, March 9, 2023 at 10:30 am Eastern Time.

Key Points: 
  • A critical mechanism of cancer immune evasion is the generation of high levels of immunosuppressive adenosine within the tumor microenvironment.
  • Portage’s virtual KOL event will discuss what can be learned from agents that target adenosine for the treatment of cancer, and how Portage plans to augment an immune response with its next-generation small molecule adenosine 2A and adenosine 2B inhibitors.
  • Lawrence Fong, M.D., is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at UCSF.
  • He also co-directs the Parker Institute for Cancer Immunotherapy at UCSF and co-leads the Cancer Immunology Program in the Helen Diller Family Comprehensive Cancer Center.

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

Retrieved on: 
Friday, February 3, 2023
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Orbis, TTD, Woman, Physician, EORTC, Diarrhea, Abdominal pain, HER2, Pneumonia, Breast cancer, IHC, Febrile neutropenia, Priority review, Patient, Education, HIV disease progression rates, Colitis, Incidence, Vomiting, Food, Gilead Sciences, Neoplasm, Risk, European Medicines Agency, Clinical, Journal of the National Comprehensive Cancer Network, Category 1, Death, NCCN, Survival, White, MD, Progression-free survival, Sacituzumab govitecan, Multimedia, TPC, Neutropenia, Neutrophil, Global Health, Type, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, PFS, Overalls, UCSF, UCSF Helen Diller Family Comprehensive Cancer Center, Pharmaceutical industry, Dietary supplement

Trodelvy is now also recommended as a Category 1, preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network® (NCCN®) as defined in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®)i.

Key Points: 
  • Trodelvy is now also recommended as a Category 1, preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network® (NCCN®) as defined in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®)i.
  • View the full release here: https://www.businesswire.com/news/home/20230131006182/en/
    “Despite decades of advances, people living with pre-treated HR+/HER2- metastatic breast cancer need new treatment options.
  • In a post-hoc analysis, data demonstrated Trodelvy’s efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients in the TROPiCS-02 trial.
  • The European Medicines Agency has also validated a Type II Variation Marketing Authorization Application for Trodelvy in HR+/HER2- metastatic breast cancer.

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform

Retrieved on: 
Thursday, November 17, 2022
Sequence, Research, Sickle Cell Anemia, a Molecular Disease, Gilead Sciences, Genetics, QBI, University, Chemistry, Mutation, Doctor of Philosophy, KRAS, Howard Hughes Medical Institute, Biotechnology, UCSF, Molecular oncology, Liquid, Norwest Venture Partners, Biomarker, Gladstone Institutes, Proteomics, Disease, Drug development, Ron Conway, Biological engineering, Pharmacology, University of California, San Francisco, Biogen, Map, Therapy, SSD, UCSF Helen Diller Family Comprehensive Cancer Center, HHMI, Drug discovery, Pharmaceutical industry, Medical imaging, Management, Rezo

SAN FRANCISCO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing. The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV Angel, Liquid 2 Ventures, and Hawktail. Rezo’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) developed by Nevan Krogan, Ph.D., director of QBI and a co-founder and chief executive officer of Rezo. Chemistry pioneer and inventor of leading drugs targeting KRAS, Kevan Shokat, Ph.D., is also a co-founder as well as a professor at UCSF, and an investigator of the Howard Hughes Medical Institute (HHMI).

Key Points: 
  • The platform enables the rapid identification and study of disease-causing protein and genetic interactions, which would be difficult to discover using traditional, often siloed, scientific methods.
  • Rezos disease-specific maps are designed to pinpoint novel, druggable targets that can be attacked with a range of treatment modalities.
  • Rezo aims to rapidly advance a pipeline of therapies, initially focused in solid tumor oncology guided by mutation and allele-specific biomarkers.
  • The companys initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships.